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Fusion to hydrophobin hFBi 
improves the catalytic Performance 
of a cytochrome P450 system
Sebastian Schulz†, Dominik Schumacher†, Daniel Raszkowski†, Marco Girhard  
and Vlada B. Urlacher*
Institute of Biochemistry, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
Cytochrome P450 monooxygenases (P450) are heme-containing enzymes that oxidize 
a broad range of substrates in the presence of molecular oxygen and NAD(P)H. For their 
activity, most P450s rely on one or two redox proteins responsible for the transfer of elec-
trons from the cofactor NAD(P)H to the heme. One of the challenges when using P450s 
in vitro, especially when non-physiological redox proteins are applied, is the inefficient 
transfer of electrons between the individual proteins resulting in non-productive con-
sumption of NAD(P)H – referred to as uncoupling. Herein, we describe the improvement 
of the coupling efficiency between a P450 and its redox partner – diflavin reductase – by 
fusing both enzymes individually to the hydrophobin HFBI  –  a small self-assembling 
protein of the fungus Trichoderma reesei. The separated monooxygenase (BMO) and 
reductase (BMR) domains of P450 BM3 from Bacillus megaterium were chosen as a 
P450-reductase model system and individually fused to HFBI. The fusion proteins could 
be expressed in soluble form in Escherichia coli. When HFBI-fused BMO and BMR were 
mixed in vitro, substantially higher coupling efficiencies were measured as compared with 
the respective non-fused enzymes. Consequently, myristic acid conversion increased up 
to 20-fold (after 6 h) and 5-fold (after 24 h). Size exclusion chromatography demonstrated 
that in vitro the hydrophobin-fused enzymes build multimeric protein assemblies. Thus, 
the higher activity is hypothesized to be due to HFBI-mediated self-assembly arranging 
BMO and BMR in close spatial proximity in aqueous solution.
Keywords: cytochrome P450 monooxygenase, P450 BM3, cYP102a1, diflavin reductase, fusion protein, 
hydrophobin, hFBi
inTrODUcTiOn
Cytochromes P450 are heme-containing monooxygenases that catalyze selective oxidations of a 
vast variety of organic molecules. Among the substrates of P450s are fatty acids, alkanes, steroids, 
terpenes, and antibiotics (Bernhardt, 1996; Bernhardt and Urlacher, 2014). The significance of these 
enzymes in biological, pharmacological, and biotechnological processes has been demonstrated 
in a large number of publications and emphasized in many reviews (Wong, 1998; Guengerich, 
2008; Julsing et al., 2008; Jung et al., 2011; Podust and Sherman, 2012; Urlacher and Girhard, 2012; 
Bernhardt, 2013; Munro et al., 2013).
For their activity, P450s require electrons ultimately derived from the cofactor NAD(P)H. Most 
P450s are not able to accept these electrons directly, but rely on redox proteins that transfer electrons 
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from NAD(P)H to the heme. Therefore, P450s can generally 
be considered as multi-protein systems composed of a heme-
containing monooxygenase component and either two redox 
proteins (a ferredoxin or flavodoxin, and a flavin-dependent 
reductase) or a diflavin cytochrome P450 reductase (Hannemann 
et al., 2007; McLean et al., 2015). Due to this multi-component 
nature of P450 systems, their biotechnological applications are 
mainly restricted to whole-cell processes.
An exceptional group of P450s is represented by the self-
sufficient flavocytochromes, in which the heme-containing 
monooxygenase is naturally fused to its redox partner in one 
polypeptide chain. This arrangement enables efficient electron 
transfer within these enzymes resulting in catalytic efficiencies 
that cannot be matched with other P450 systems (Girvan et al., 
2006; McLean et  al., 2007). Self-sufficient P450s, therefore, 
demonstrate in most cases higher catalytic activities among 
P450 systems (Munro et  al., 2013). For example, the highest 
ever measured turnover rate of a P450 of 17,100  min−1 was 
reported for conversion of arachidonate by the self-sufficient 
P450 BM3 (CYP102A1) from Bacillus megaterium (Noble et al., 
1999). In addition, by expression of P450 BM3 on the surface of 
Escherichia coli cells with the Autodisplay system, which allowed 
several re-uses of the catalyst, a total turnover number of up to 
54,700 could be reached – the highest value reported for a P450 
to date (Ströhle et al., 2016).
Consequently, one approach to reduce the complexity of 
P450 multi-protein systems is the construction of “artificial” 
self-sufficient fusion proteins. A number of mammalian, plant, 
and bacterial P450s have been fused either to their cognate redox 
partners or to “foreign” heterologous redox proteins if cognate 
ones could not be identified [reviewed in Hlavica (2009) and 
Sadeghi and Gilardi (2013)]. For example, in a recent study, 
the “artificial” fusion of Panax ginseng cytochrome P450-type 
protopanaxadiol synthase (PPDS) and Arabidopsis thaliana 
NADPH-cytochrome P450 reductase (ATR1) was described 
(Zhao et al., 2016). When expressed in Saccharomyces cerevisiae, 
the PPDS–ATR1 fusion enzymes conferred a 4.5-fold increase 
in catalytic activity and 71.1% increase in protopanaxadiol 
production compared with PPDS and ATR1 co-expression 
(Zhao et  al., 2016). In another recent study, a plant P450 fla-
vonoid 3′-hydroxylase (F3′H), was functionally expressed as 
a fusion protein with a P450 reductase (CPR) in E. coli and 
successfully employed to produce eriodictyol – a flavonoid with 
anti-inflammatory and antioxidant activities – from l-tyrosine 
(Zhu et al., 2014).
However, the generation of artificial fusion proteins is, on the 
one hand, restricted to an equimolar ratio of redox partner(s):P450 
(1:1) and, on the other hand, can significantly restrict the struc-
tural flexibility of the individual proteins. Therefore, such artifi-
cial fusions do not necessarily end up showing improved catalytic 
performance (Sibbesen et al., 1996; Cao et al., 2000).
Especially with regard to biocatalytic applications of P450s, 
in which high catalytic activities are required, efficient P450-
reductase interactions are of tremendous importance (Munro 
et  al., 2007; Bernhardt and Urlacher, 2014). In search for a 
method that allows for site-specific protein targeting and higher 
flexibility of the partner proteins, an approach called “PUPPET” 
has been introduced to improve interaction of P450s with redox 
proteins (Hirakawa and Nagamune, 2010). PUPPET is based on 
a fusion approach employing the self-assembling heterotrimeric 
“proliferating cell nuclear antigen” (PCNA) as a scaffold and has 
been used for P450cam from Pseudomona putida and its cognate 
redox proteins putidaredoxin reductase (PdR) and putidare-
doxin (Pdx) (Hirakawa and Nagamune, 2010). Compared with 
an equimolar mixture of non-fused P450cam:PdR:Pdx in vitro, 
PUPPET displayed a substantially higher catalytic activity, which 
was explained by improved electron transfer due to the extreme 
proximity of the P450 and redox partner proteins within the 
formed complex. However, the trimeric complex dissociated 
at low concentrations, a problem that was solved by selective 
introduction of covalent disulfide bridges (Hirakawa et  al., 
2013). PUPPET is also applicable for P450s whose cognate redox 
partners are not yet identified, as demonstrated for CYP119 
from Sulfolobus solfataricus (Suzuki et  al., 2014). The PCNA-
mediated heterotrimerization of CYP119/PdR/Pdx enhanced 
CYP119 activity, explained by the authors as a result of high 
local concentrations of the two redox proteins PdR/Pdx toward 
CYP119. However, a limitation of PUPPET is that due to the 
trimeric nature of PCNA, this method is restricted to equimolar 
concentrations of redox proteins and P450.
It has been demonstrated in many studies that substrate 
turnovers by P450s were greatly improved by using the electron 
transfer proteins in molar excess (Girhard et al., 2010; Bell et al., 
2012; Cheng et al., 2012; Brill et al., 2014), which is likely due to 
the higher probability of a P450 to encounter the redox partners in 
solution. At the same time, the requirement of a high molar excess 
of redox proteins (e.g., more than 10 times excess of iron–sulfur 
proteins for class I P450s) is a critical bottleneck in practical P450 
applications (Hirakawa et al., 2007).
In view of this requirement, we aimed to establish a novel 
system that does not underlie the restrictions of equimolar redox 
protein:P450 concentrations. To achieve this goal, a self-assem-
bling protein is required capable of forming multimers larger 
than dimers or trimers in solution. We chose hydrophobins, 
small fungal proteins of about 100 amino acids with a ubiquitous 
presence of eight cysteine residues forming four disulfide bonds 
(Wösten and de Vocht, 2000; Bayry et al., 2012). Hydrophobins are 
amphiphilic molecules comprising a hydrophilic protein part as 
well as a hydrophobic patch region, which enables these proteins 
to self-assemble in aqueous solutions as multimers, e.g., tetramers 
(Szilvay et al., 2006), as well as at hydrophilic–hydrophobic inter-
faces into organized monolayer membranes (Linder, 2009; Ley 
et al., 2015) (Figure 1A). The self-assembly in aqueous solution is 
likely based on hydrophobic–hydrophobic interactions between 
the hydrophobic patches of hydrophobin monomers (Hakanpää 
et al., 2006; Szilvay et al., 2006).
The intensively studied hydrophobin HFBI from Trichoderma 
reesei (Nakari-Setälä et  al., 1996; Hakanpää et  al., 2006) was 
applied as self-assembling component in our study, as formation 
of multimers of a fusion protein consisting of an endoglucanase 
and HFBI in solution has been described and putative decamers 
have been suggested (Linder et al., 2002).
For this proof-of-concept study, we used the individual domains 
of P450 BM3 from B. megaterium. The holoenzyme P450 BM3 is 
FigUre 1 | (a) Self-assembly of HFBI at hydrophobic or hydrophilic supports reverses the supports’ wettability; self-assembly in aqueous solution is based on 
hydrophobic–hydrophobic interactions between the hydrophobic patches of HFBI monomers. (B) Schematic drawing of HFBI-fused and non-fused proteins. 
Subscript numerals in ‘BMO’ and ‘BMR’ indicate amino acid positions based on the respective holoenzyme P450 BM3. His6: N-terminal hexa-histidine tag. 
(c) Schematic drawings of the BMO/BMR system (the dimensions of the individual proteins are not scaled). Since non-fused BMO and BMR diffuse freely in solution 
and encounter each other by coincidence (left side), uncoupling reactions result in electrons transferred to O2 and lead to formation of reactive oxygen-species 
(e.g., H2O2). In the hypothesized HFBI-fusion model (right side), BMO–HFBI and BMR–HFBI are arranged in close spatial proximity by self-assembly of HFBI resulting 
in reduced uncoupling and improved catalytic performance. The illustrations show octa, tetra, and dimer formation as examples, but other multimeric assemblies are 
also conceivable. R-H, substrate; R-OH, hydroxylated product.
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a natural fusion consisting of a heme-containing monooxygenase 
(BMO) linked to an FAD-FMN-containing diflavin reductase 
(BMR) (Narhi and Fulco, 1987). Earlier studies demonstrated 
that the individual domains can be separated and when reconsti-
tuted in vitro, activity was observed (Boddupalli et al., 1992a), but 
at drastically reduced levels as compared with the holoenzyme 
(4,000 versus 0.5 mol min−1 molP450−1 measured with palmitic acid 
for the holoenzyme P450 BM3 versus BMO:BMR reconstituted at 
a 1:10 ratio, respectively) (Sevrioukova et al., 1997).
Herein, the separated BMO- and BMR domains were 
individually fused to the hydrophobin HFBI (Figure  1B). The 
artificial fusion proteins were expressed in E. coli and purified. 
Their combination in different molar ratios in vitro resulted in 
increased coupling efficiencies and substrate conversions. These 
improvements are hypothesized to originate from hydrophobin-
mediated self-assembly between BMO and BMR (Figure 1C).
MaTerials anD MeThODs
generation of hFBi-Fused Proteins
Plasmids containing the genes coding for BMO1–472 and 
BMR473–1049 inserted into pET-28a(+) were generated previously 
(Girhard et al., 2007; Weber et al., 2010). The subscript numbers 
refer to the amino acid positions in the holoenzyme P450 BM3 
encoded by the cyp102a1-gene (GenBank J04832), and are 
counted including the first methionine.
The open reading frame of the hfb1-gene encoding full-length 
HFBI1–97 from T. reesei (GenBank Z68124) was codon-optimized 
for expression in E. coli and obtained as synthetic gene from 
GeneArt (Germany).
Individual genes encoding BMO1–472, BMR473–1049 and mature 
HFBI23–97 (lacking the N-terminal secretion signal) were amplified 
by PCR and applied for the generation of HFBI-fused proteins. 
Primers introduced a sequence encoding the flexible glycine-rich 
linker [GGGGS]2. Details of primer sequences and PCR are given 
in the Tables S1–S4 in Supplementary Material. Fusion constructs 
were generated by overlap-extension PCR (oePCR). C-terminal 
fusions (BMO–HFBI and BMR–HFBI) were generated by a 
one-step oePCR in which all reaction ingredients were present in 
the initial reaction mixture. For generation of N-terminal fusion 
constructs (HFBI–BMO and HFBI–BMR), a two-step oePCR 
was applied in which the terminal primers were added after the 
first seven PCR cycles. Forward primers introduced an EcoRI 
and reverse primers a XhoI restriction site enabling ligation into 
the expression vector pET-28a(+). All genes were cloned in pET-
28a(+) and carried an N-terminal His6-tag. The resulting plas-
mids were propagated in E. coli DH5α and gene sequences were 
confirmed by Sanger sequencing (GATC-Biotech, Germany).
Protein expression
The E. coli strain Shuffle T7 Express was used for expression of all 
enzymes, except for the holoenzyme P450 BM3 that was expressed 
using strain BL21(DE3) (both strains from New England Biolabs, 
Germany). Four hundred  milliliters of cultures (Lysogeny broth 
containing 30 μg ml−1 kanamycin) were grown at 37°C, 180 rpm 
on an orbital shaker until the optical density at 600 nm (OD600) 
reached ~0.8. At this point, expression was induced with 100 μM 
isopropyl β-d-1-thiogalactopyranoside (IPTG). In case of P450 
expressions (holoenzyme P450 BM3, BMO–HFBI, HFBI-BMO 
and BMO), the cultures were supplemented with 80  μg  ml−1 
5′-aminolevulinic acid and 100 μM FeSO4. After induction, pro-
tein expression was done at 30°C, 140 rpm. Cells were harvested 
by centrifugation (18,000× g, 30 min, 4°C). The cell pellets were 
resuspended in 50 mM potassium phosphate buffer (KPi), pH 7.5 
containing 5% (v/v) glycerol, and 100 μM phenylmethylsulfonyl 
fluoride (PMSF), disrupted by sonication on ice (3 ×  1.5  min, 
1  min intermission), and cell debris was removed by centrifu-
gation (49,000× g, 30 min, 4°C). The supernatants (cleared cell 
lysates) were recovered and stored at −20°C until purification.
Protein Purification, sDs-Page, 
and immunodetection
Protein purification was done by immobilized metal ion affin-
ity chromatography (IMAC) using a HisTrap FF crude column 
(2 × 5 ml) on an ÄKTApurifier system (GE Healthcare, Germany). 
The column was equilibrated with 50 mM KPi, pH 7.5, 500 mM 
NaCl prior to loading of the protein sample. Non-specifically 
bound proteins were washed off the column with three column 
volumes (CV) of the same buffer and five CV of the buffer con-
taining 7.5–25 mM imidazole. The protein of interest was eluted 
with buffer containing 200 mM imidazole.
Purified proteins were desalted with a HiPrep 26/10 desalt-
ing column (GE Healthcare) and eluted in 50 mM KPi, pH 7.5, 
25 mM NaCl, 5% (v/v) glycerol. Protein samples were concen-
trated by ultrafiltration (30  kDa molecular weight cutoff) and 
stored at −20°C.
Proteins were visualized by SDS-PAGE (Laemmli, 1970) as 
well as Western blotting in combination with immunodetection 
using an antibody recognizing the His6-tag epitope. Semi-dry 
transfer of proteins onto nitrocellulose membranes was con-
ducted with 2  mA/cm2 for 30  min. Membranes were blocked 
with TBST [50 mM TrisHCl, pH 7.5, 150 mM NaCl, 0.1% (v/v) 
Tween 20] containing 1% (w/v) skimmed milk powder for 1 h 
and incubated for another 1.5  h with an Anti-His6-peroxidase 
conjugate (Anti-His6-peroxidase mouse IgG, Roche Diagnostics, 
Germany) according to the manufacturer’s instructions. After 
three washing steps with TBST, the precipitating BM Blue POD 
substrate (Roche Diagnostics) was applied for immunodetection 
following the supplier’s instructions.
size exclusion chromatography
Assembly of BMO–HFBI/BMR–HFBI was analyzed by size exclu-
sion chromatography (SEC) on a 16/60 Superdex 200 prep grade 
column (GE Healthcare) with a bed volume of 120 ml and a sepa-
ration range of 10–600 kDa. The column was equilibrated with 3 
CV of 50 mM KPi, pH 7.5, 5% (v/v) glycerol prior to loading 1 ml 
of protein samples. Samples containing an equimolar mixture of 
BMR-HFBI and BMO-HFBI (53 μM each) were incubated for 
30 min at 30°C prior to loading. Proteins were eluted at a flow 
rate of 0.5 ml min−1 in 1.5 CV buffer and detected by measuring 
the absorbance at 280  nm. To estimate molecular weights, the 
standard proteins apoferritin (equine spleen; 443 kDa), β-amylase 
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(potato; 200 kDa), alcohol dehydrogenase (yeast; 150 kDa), albu-
min (bovine serum; 66  kDa), and carbonic anhydrase (bovine 
erythrocytes; 29 kDa) (all from Sigma-Aldrich, Germany) were 
used, whereas the exclusion limit of the column (≥ 600 kDa) was 
determined by using blue dextran (elution volume 40.8 ml).
Determination of Protein concentrations
The concentrations of diflavin reductase containing enzymes 
were calculated from the absorbance at 452 and 466  nm with 
ε452 = 10 mM−1 cm−1 and ε466 = 10 mM−1 cm−1 (Sevrioukova et al., 
1996). Concentrations of P450 containing enzymes were calcu-
lated from CO-difference spectra with ε450-490 = 91 mM−1 cm−1 as 
described elsewhere (Omura and Sato, 1964b).
Total protein concentrations were determined using the 
method described by Bradford (1976) and bovine serum albumin 
as standard.
cytochrome c assay
Cytochrome c reducing activities of reductases were determined 
in 96-microwell plates in total volumes of 200  μl containing 
50 mM KPi, pH 7.5, and 100 μM cytochrome c from equine heart 
(Sigma-Aldrich). Reactions were started by addition of 100 μM 
NADPH. The increase of absorbance at 550  nm was followed 
and cytochrome c reducing activities were calculated using 
ε550 = 21 mM−1 cm−1. Specific activities are given in U mg−1 of total 
protein, where 1 U is defined as the amount of enzyme catalyzing 
the reduction of 1 μmol cytochrome c per minute. Cytochrome c 
reducing activities of soluble protein fractions obtained from 
E. coli cells lacking expressed heterologous reductase were sub-
tracted from the results.
Bioconversion of Myristic acid 
and Product analysis
Conversions of myristic acid were performed at 30°C in a total 
reaction volume of 300 μl. Samples contained 50 mM KPi, pH 
7.5, 1 mM MgCl2, 2% (v/v) DMSO, 200 μM myristic acid, 4 mM 
d-glucose 6-phosphate, and 3 U glucose 6-phosphate dehydro-
genase from Leuconostoc mesenteroides (Sigma-Aldrich) for 
cofactor regeneration, 600 U catalase from bovine liver (Sigma-
Aldrich) to decompose hydrogen peroxide that can be produced 
within the P450 catalytic cycle, 200 μM NADPH, 1 μM P450 
(BMO–HFBI or BMO), and 1 or 5 μM reductase (BMR–HFBI 
or BMR). Additionally, a reaction was set up that contained 1 μM 
holoenzyme P450 BM3 instead of BMO and BMR.
Analysis of reaction products was done by gas chromatogra-
phy coupled with mass spectrometry (GC/MS). Samples were 
acidified with HCl, extracted with diethyl ether, derivatized 
with N,O-bis(trimethylsilyl)trifluoroacetamide containing 1% 
trimethylchlorosilane, and analyzed, as described previously 
(Girhard et al., 2013).
Measurement of naDPh Oxidation 
rates and coupling efficiencies
NADPH oxidation rates as well as coupling efficiencies were 
determined in a total reaction volume of 1 ml. Samples contained 
50 mM KPi, pH 7.5, 2% (v/v) DMSO, 200 μM myristic acid, 1 μM 
P450 (BMO–HFBI or BMO), and 1 or 5 μM reductase (BMR–
HFBI or BMR). Additionally, a reaction was set up that contained 
1 μM holoenzyme P450 BM3 instead of BMO and BMR.
Reactions were started by addition of 200 μM NADPH and the 
absorbance decrease at 340 nm was followed. NADPH oxidation 
rates were calculated using ε340 = 6.22 mM−1 cm−1 and related to 
the applied amount of P450 (nmol min−1 nmolP450−1).
After NADPH was completely consumed, the samples were 
prepared for GC/MS analysis as described above. The coupling 
efficiencies were calculated as the ratio between the concentra-
tions of product formed and NADPH consumed.
resUlTs
expression and characterization  
of hFBi-Fused Proteins
The two domains of P450 BM3, the monooxygenase domain 
BMO and the diflavin reductase domain BMR were separated and 
fused individually to hydrophobin HFBI. Fusion proteins were 
constructed using the mature form of hydrophobin HFBI lacking 
its N-terminal 22 amino acids-long secretion signal sequence. 
HFBI was fused to BMO and BMR in two orientations: either at 
their N-termini (designated as HFBI–BMO and HFBI–BMR) or 
at their C-termini (designated as BMO–HFBI and BMR–HFBI) 
(Figure  1B). We inserted a flexible [GGGGS]2 linker, because 
this linker type is frequently used for the construction of fusion 
proteins allowing for motility of separate domains (Lu and 
Feng, 2008; Gruner et al., 2012; Chen et al., 2013; Bakkes et al., 
2015). Due to the large differences in molecular weights of HFBI 
(7.5  kDa) and BMO or BMR (54 and 64  kDa, respectively), a 
flexible but not too long linker was considered suitable to retain 
the functional integrity of both domains; especially the self-
assembling capability of the rather small HFBI domain should 
not be superposed by the larger BMO or BMR domains. The 
separated non-fused BMO and BMR domains served as refer-
ence proteins for comparison of biochemical and biocatalytic 
properties.
The four disulfide bridges present in hydrophobins stabilize 
their structure as described for HFBII (Hakanpää et al., 2004). As 
HFBI possesses a very similar overall structure (Hakanpää et al., 
2006), we used the E. coli Shuffle T7 Express strain optimized 
for functional expression of proteins bearing disulfide bridges to 
express the HFBI fusion proteins. The same strain has also been 
applied for the expression of other HFBI fusion proteins earlier 
(Gruner et al., 2012).
Expression of the C-terminal HFBI fusions, BMO–HFBI 
(Figure 2A) and BMR–HFBI (Figure 2B) resulted in adequate 
amounts of soluble protein. The N-terminal fusions HFBI–BMO 
and HFBI–BMR were expressed at lower levels compared with the 
C-terminal fusions. Western blot analysis indicated only a slight 
soluble expression of HFBI–BMO (~30%) which was, however, 
entirely absent in case of HFBI–BMR with all protein detected as 
insoluble (Figures S1 and S2 in Supplementary Material).
Non-fused BMO was almost exclusively found soluble, 
whereas ~50% of non-fused BMR built insoluble aggregates dur-
ing expression (Figure S3 in Supplementary Material).
TaBle 1 | expression of BMO-enzymes and cytochrome c reducing 
activities of BMr-enzymes (soluble protein fractions after cell lysis).
enzyme expression (nmol l−1) cytochrome c activity (U mg−1)
BMO–HFBI 650 –
HFBI–BMO n.d. –
BMO 1,100 –
BMR–HFBI – 0.88
HFBI–BMR – 0.03
BMR – 1.04
n.d., not detectable; –, not measured.
FigUre 2 | sDs-Page (top pictures) and immunodetection (bottom pictures) of c-terminal hFBi-fusion proteins expressed in E. coli shuffle T7 
express. (a) BMO–HFBI and (B) BMR–HFBI. (1) Whole-cells before induction; (2) cells 1 h post-induction; (3) cells 2 h post-induction; (4) cells 3 h post-induction; 
(5) cells 4 h post-induction; (6) purified BMO–HFBI or BMR–HFBI of cells harvested 18 h post-induction; (7) purified non-fused BMR or BMO of cells harvested 18 h 
post-induction. BMO–HFBI (66 kDa) and BMR–HFBI (76 kDa) are marked with a full arrow. Non-fused BMO (57 kDa) and BMR (68 kDa) are marked with an open 
arrow. Approximately 10 μg total protein per lane. M, molecular weight marker.
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Soluble protein fractions bearing the heme-containing 
BMO domain were analyzed by recording CO-difference 
spectra that provides a measure of functional P450 based 
on correctly coordinated heme (Omura and Sato, 1964a,b). 
Generally, the observations from SDS-PAGE and immuno-
detection were in good agreement with the measurement 
of functional P450 in the soluble protein fractions. The 
C-terminal BMO–HFBI fusion was expressed at 650 nmol l−1, 
whereas no correctly folded P450 was detectable in the sam-
ples with the N-terminal HFBI–BMO fusion. For compari-
son, the non-fused BMO was expressed at a concentration of 
1,100 nmol l−1 (Table 1).
Soluble protein fractions containing the BMR domain were 
assessed for their ability to reduce cytochrome c. Samples con-
taining the C-terminal BMR–HFBI fusion displayed a 29-fold 
higher cytochrome c reducing activity compared with that of the 
N-terminal HFBI–BMR fusion, which showed a very low activity 
of 0.03 U mg−1. Non-fused BMR displayed a slightly higher activ-
ity compared with that of BMR–HFBI (Table 1).
Since adequate expression and activity were obtained for the 
C-terminal fusion proteins only, BMO–HFBI and BMR–HFBI 
were selected for all further experiments.
After IMAC-purification, SDS-PAGE of BMO–HFBI and 
BMR–HFBI revealed protein bands of the expected molecular 
masses. However, an additional band migrating slightly below the 
expected one was visible for both fusions. Both bands remained 
visible on a Western blot (Figure 2). As immunodetection was 
done using an antibody directed against the His6-tag epitope 
located on the N-terminus, we suggest that the degradation of 
fusion proteins occurred from their C-termini. If expressions 
were conducted for longer time periods of 18 h, the degradation 
was even more pronounced yielding higher ratios of truncated 
than intact fusion proteins. Therefore, the expression times were 
shortened to 2–6 h to ensure high yields of functional full-length 
fusion proteins.
CO-difference spectra of purified BMO–HFBI and BMO 
showed the characteristic P450 absorbance maximum around 
FigUre 3 | spectral properties of hFBi-fused and non-fused BMO and BMr. (a) CO-difference spectra of purified BMO–HFBI (solid line) and BMO (dotted 
line). (B) Absorbance spectra of purified BMR–HFBI (solid line) and BMR (dotted line).
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450 nm, indicating correctly coordinated heme; specifically, the 
absorbance maximum was observed at 449 nm for both proteins 
(Figure 3A). Absorbance spectra of purified BMR showed maxima 
at 383 and 457 nm, which is in good agreement with literature 
data reporting maxima at 385 and 456 nm (Neeli et al., 2005). 
Values for purified BMR–HFBI were very similar with maxima at 
385 and 457 nm (Figure 3B). Both spectra indicate the presence 
of two prosthetic groups, namely FAD and FMN. In contrast to 
BMR, however, in the BMR–HFBI spectrum the 457 nm maxi-
mum was less pronounced compared with the 385 nm maximum 
and had an additional plateau around 403–411 nm.
Myristic acid conversion by hFBi-Fused 
Proteins
To assess the activity of HFBI-fused enzymes, myristic acid – a 
well-studied substrate of the holoenzyme P450 BM3 (Boddupalli 
et  al., 1992b; Whitehouse et  al., 2012)  –  was chosen as model 
substrate. The holoenzyme P450 BM3 catalyzes the oxidation 
of myristic acid at subterminal positions to give predominantly 
the ω-1, ω-2, and ω-3 hydroxylated products (Figure S4 in 
Supplementary Material).
In the first experiment, hydrophobin-fused BMO–HFBI and 
BMR–HFBI were mixed in vitro in equimolar ratio and conver-
sion of myristic acid was compared with those of non-fused BMO 
and BMR. Conversion with BMO–HFBI/BMR–HFBI achieved 
78 and 99% after 6 and 24 h, whereas for BMO/BMR only 3.9 
and 19% conversion was observed within these periods of time, 
respectively (Figure 4A).
As described in the Section “Introduction,” P450 systems can 
generally be improved by using the electron transfer proteins in 
a molar excess (Girhard et al., 2010; Bell et al., 2012; Cheng et al., 
2012; Brill et al., 2014). Thus, in a second experiment, myristic acid 
conversion was assayed with fivefold molar excess of BMR–HFBI 
over BMO–HFBI. In this case, conversion with BMO–HFBI/
BMR–HFBI was almost complete after 2 h (97%), whereas reac-
tions with BMO/BMR required 6 h to convert the same amount of 
myristic acid (Figure 4B). When comparing the reaction system 
with equimolar P450:reductase ratios to those employing fivefold 
excess of reductase, it can be stated that the improvement of the 
system by fusion to HFBI was more pronounced if the proteins 
were applied in equimolar ratio.
Next, we aimed to investigate whether the observed improve-
ments in myristic acid conversion could also be achieved if only 
one of the partners was fused to HFBI. Hence, “cross-conversion” 
experiments were performed, in which a HFBI-fused protein 
was combined with the corresponding non-fused partner [(i) 
BMO/BMR–HFBI and (ii) BMO–HFBI/BMR], and were con-
ducted using a fivefold molar excess of the reductase. In these 
cases, the conversions of myristic acid reached 57–60% after 2 h 
(Figure 4C), which is lower compared with the 97% reached with 
both partners fused to HFBI (BMO–HFBI/BMR–HFBI), and 
interestingly also slightly lower compared with the reaction with 
non-fused BMO/BMR (74%).
For all reconstituted systems predominantly ω-1 hydroxylated 
myristic acid and similar ratios of ω-2 and ω-3 hydroxylated 
products were observed, which is in agreement with the literature 
data for the holoenzyme P450 BM3 (Boddupalli et  al., 1992b; 
Whitehouse et al., 2012). The product distributions of both fused 
and non-fused systems were overall similar; thus, the fusion of 
HFBI did not affect the regioselectivity of BMO (Table S5 in 
Supplementary Material).
catalytic Performance of hFBi-Fused 
Proteins
The HFBI-fused proteins were analyzed in more detail regarding 
NADPH oxidation rates and coupling efficiencies during myristic 
acid hydroxylation (Table  2). When BMO–HFBI/BMR–HFBI 
were applied in equimolar ratio, an NADPH oxidation rate of 
4.2 nmol min−1 nmolP450−1 was measured, and the coupling effi-
ciency between NADPH consumed and product formed reached 
57%. A fivefold molar excess of BMR–HFBI resulted in a sixfold 
increased NADPH oxidation rate (27.0 nmol min−1 nmolP450−1) 
compared with the equimolar reconstituted HFBI-system. 
Strikingly, the coupling efficiency was increased to 93%.
TaBle 2 | catalytic performance of reconstituted P450-reductase systems.
enzymes ratio 
P450:reductase
naDPh oxidation  
ratea
coupling 
efficiency (%)
BMO–HFBI/
BMR–HFBI
1:1 4.2 ± 0.1 57.4 ± 16.6
BMO/BMR 1:1 n.d.b –c
BMO–HFBI/
BMR–HFBI
1:5 27.0 ± 7.2 92.7 ± 4.8
BMO/BMR 1:5 26.2 ± 9.8 65.2 ± 16.3
Holoenzyme 
P450 BM3
368.6 ± 52.3 91 ± 1.1
aInitial NADPH oxidation rate (nmol min−1 nmolP450−1).
bNot detectable (NADPH consumption and substrate conversion were below the 
detection limits).
cDue to non-detectable NADPH consumption and substrate conversion, the coupling 
efficiency could not be determined.
FigUre 4 | conversions of myristic acid by reconstituted P450/
reductase systems in vitro. BMO–HFBI/BMR–HFBI (filled squares) in 
comparison to BMO/BMR (open circles) (a) equimolar ratios (1:1 μM). 
(B) Fivefold molar excess of reductase (1:5 μM). Mean ± SD (n = 3). 
(c) “Cross-conversion” experiment with a HFBI-fused and a corresponding 
non-fused protein. BMO/BMR–HFBI (open diamonds) or BMO–HFBI/BMR 
(open triangles), both with fivefold molar excess of the reductase (1:5 μM). 
Mean ± SD (n = 2).
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In comparison, for the equimolar mixture of non-fused BMO/
BMR, the NADPH oxidation rate and coupling efficiency were 
too low to be quantified. For the 1:5 mixture of BMO/BMR, the 
NADPH oxidation rate reached 26.2 nmol min−1 nmolP450−1, which 
is comparable to those of the fused enzymes; however, a much 
lower coupling efficiency was measured in this case (Table 2).
The NADPH consumption rate of the holoenzyme P450 BM3 
was still 14-fold higher (368.6 nmol min−1 nmolP450−1) than that 
of the HFBI-fused system with fivefold excess of reductase and 
100% conversion was achieved already within the first 5  min 
of the reaction (data not shown), but remarkably, the coupling 
efficiency was about the same (91%).
The myristic acid conversions obtained after 2 h with cofactor 
regeneration (Figure 4) were in good agreement with the obtained 
coupling efficiencies of the reconstituted systems. The highest 
conversion of 97% was achieved with BMO–HFBI/BMR–HFBI 
with fivefold excess of reductase (Figure  4B). For this system, 
accordingly the highest coupling efficiency was determined. For 
equimolar reconstituted systems, conversion after 2 h was only 
detectable in reactions with BMO–HFBI/BMR–HFBI (49%) 
which was accompanied with measurable NADPH oxidation 
rates and coupling efficiency. By contrast, catalytic parameters 
and conversion were not detectable when non-fused BMO/BMR 
was reconstituted in equimolar 1:1 ratio.
size exclusion chromatography 
experiments
We hypothesized that, in aqueous solutions, the self-assembling 
capability of hydrophobins arranges the monooxygenase and 
reductase domains in close spatial proximity, consequently 
increasing the catalytic performance of the reconstituted system. 
Indeed, the HFBI-fused enzymes displayed improved catalytic 
performance compared with the non-fused enzymes indepen-
dently on the molar ratio employed. To gain a first hint, if this 
improvement is in fact due to self-assembling of the HFBI-fusion 
proteins, an equimolar mixture of BMO–HFBI/BMR–HFBI (66 
and 76  kDa molecular weight of monomers) was analyzed by 
SEC (Figure 5). The elution profile of the HFBI-fused enzymes 
showed multiple peaks, which is indicative of a heterogeneous 
protein population. The largest peak eluted at 43.6 ml, which cor-
responds to a molecular weight of ~530 kDa. The high-molecular 
weight species are multimeric assemblies; here, putative hexa- to 
octameric complexes are conceivable. Moreover, additional 
peaks were detected corresponding to species with an apparent 
FigUre 5 | size exclusion chromatography of a mixture of BMO-
hFBi:BMr–hFBi in equimolar ratio (53 μM each). The void volume of the 
column was 40.8 ml (≥600 kDa). Molecular weights were estimated using a 
linear calibration curve with standard proteins (for details refer to Section 
“Materials and Methods”). Peak 1, ca. 530 kDa (43.6 ml); Peak 2, 276 kDa 
(52.5 ml); Peak 3, 143 kDa (61.4 ml); Peak 4, 78 kDa (69.6 ml). Peaks eluting 
between 100 and 120 ml (designated with asterisks) denote molecular 
weights smaller than 29 kDa and likely represent degradation products.
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molecular weight of 276 kDa (putative tetramer), 143 kDa (puta-
tive dimer), and 78 kDa (likely the monomers).
Although the exact compositions of the different multimeric 
complexes formed by HFBI-fused enzymes – including the stoi-
chiometry in which the individual BMO and BMR components 
are present –  remained unidentified, the presence of octa- and 
other multimers gives a good hint that the HFBI-fused proteins 
are able to self-assemble in solution.
DiscUssiOn
The capability of hydrophobin HFBI to self-assemble was analyzed 
in this study for its potential to improve the catalytic performance 
of a reconstituted in vitro system consisting of a P450 monooxy-
genase and its corresponding diflavin reductase. Therefore, the 
HFBI moiety was fused individually to BMO and BMR.
It has been described previously that expression of hydro-
phobins in E. coli often leads to formation of inclusion bodies 
(Espino-Rammer et al., 2013), which also accounts for derived 
fusion proteins (Morris et  al., 2013). Isolation from insoluble 
protein fractions is conducted with denaturing agents followed 
by oxidative refolding (Morris et  al., 2013). Within this study, 
expression of soluble and functional proteins was only possible in 
case of C-terminal HFBI-fusion (BMO–HFBI and BMR–HFBI). 
By contrast, expressions of fusion proteins bearing HFBI at their 
N-termini yielded largely insoluble and non-functional proteins. 
A similar expression strategy was employed using glutathione 
S-transferase (GST) as N-terminal fusion partner leading to solu-
ble expression of GST-hydrophobin fusion proteins. GST was even 
necessary to keep the class II hydrophobins HFBIV and HFBVII 
in solution in in vitro experiments (Espino-Rammer et al., 2013). 
Similarly, Morris et al. (2011) reported soluble expression of the 
class I hydrophobin DewA from Aspergillus nidulans, which was 
produced as a fusion protein with N-terminally located human 
ubiquitin. In accordance to the literature, our data indicate that 
soluble expression of HFBI in E. coli is favored by fusion of a highly 
soluble large protein (like BMO or BMR) to the N-terminus of 
HFBI.
Spectra of purified BMO–HFBI and BMR–HFBI were very 
similar to that of their non-fused counterparts BMO and BMR. 
The CO-difference spectrum of BMO–HFBI indicated a proper 
incorporation of the heme group during expression of the fusion. 
The absorbance spectrum of BMR–HFBI showed two specific 
maxima indicative for FAD–FMN-bound diflavin reductases 
(Sevrioukova et al., 1996; Neeli et al., 2005). The ratios of maxima 
between BMR–HFBI and BMR were different, and BMR–HFBI 
showed an additional shoulder at 403–411  nm. The observed 
differences are probably due to the fact that HFBI was fused to 
the C-terminus of BMR near the FAD coordination site. Similar 
albeit less pronounced observations were made previously in 
mutagenesis studies focusing on the NADPH-binding FAD-
region of BMR. In that case, the ratios between shorter and longer 
wavelength maxima were also changed which was explained 
by the exposure of FAD to the solvent (Neeli et al., 2005). The 
shoulder at 403–411 nm might be explained by the presence of 
a certain fraction of anionic FAD− radicals (Müller et al., 2014).
We observed that with increasing expression time HFBI-fused 
proteins were not entirely expressed in intact full-length form. 
Degradation products derived from C-terminal truncation were 
frequently observed at longer expression times. On SDS-gels, 
degradation products of BMO–HFBI and BMR–HFBI migrated 
approximately at molecular masses comparable to those of non-
fused BMO and BMR, respectively. This is likely the result of 
cleavage of the glycine-serine linker leading to HFBI-deficient 
protein subspecies. Gycine-rich linkers were previously found to 
be prone to proteolytic cleavage by E. coli peptidases (Kavoosi 
et al., 2007) which might provide an explanation for our observa-
tion. Furthermore, degradation of fusion proteins bearing the 
hydrophobin DewA were described as well (Wohlleben et  al., 
2010). A systematic optimization of the linker sequence between 
both fusion partners, e.g., by the recently described “DuaLinX” 
method (Bakkes et al., 2015), may lead to enhanced stability of 
the fusion proteins.
Catalytic activity of the BMO–HFBI/BMR–HFBI system was 
higher as compared with that of the respective non-fused BMO/
BMR system. The catalytic performance was assessed in two ways: 
(i) time-dependent substrate conversion using cofactor regenera-
tion and (ii) the assessment of catalytic parameters of reconsti-
tuted systems by measurements of initial rates under cofactor 
limiting conditions. Both methods independently confirmed a 
beneficial effect of the HFBI-fusion on catalytic performance. 
This effect was more pronounced when reconstituted in equimo-
lar ratio, but also visible at a 1:5 ratio of BMO-HFBI:BMR-HFBI. 
Furthermore, fusion to HFBI did not affect the regioselectivity of 
BMO in myristic acid hydroxylation.
Remarkably, the coupling efficiency of the BMO–HFBI/
BMR–HFBI reaction reached up to 93%, which is as good as that 
of the holoenzyme P450 BM3. This improvement is hypothesized 
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to originate from more efficient electron transfer from BMR to 
BMO as result of HFBI-mediated assembly of the proteins in 
close spatial arrangement in solution. Our SEC data support 
this hypothesis, since high-molecular weight complexes were 
observed for equimolar mixtures of BMO–HFBI/BMR–HFBI. 
The elucidation of the exact nature of these multimeric complexes, 
however, requires further studies.
In conclusion, the presented approach employing the hydro-
phobin HFBI to mediate P450-reductase interaction represents 
a promising tool for the improvement of the catalytic perfor-
mance of multi-component P450 systems. Since redox partners’ 
ratios can be flexibly adjusted, the system can be fine-tuned 
according to the needs of individual P450s. The hydrophobin 
fusion approach might also be extended to other multi-enzyme 
systems where arrangement of the individual enzymes in close 
spatial proximity is a prerequisite to achieve high catalytic 
activities.
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